Serum lycopene concentration and prostate cancer risk: Results from the prostate cancer prevention trial

Alan R. Kristal, Cathee Till, Elizabeth A. Platz, Xiaoling Song, Irena B. King, Marian L. Neuhouser, Christine B. Ambrosone, Ian M. Thompson

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Background: Lycopene has been promoted for prostate cancer prevention, despite the inconsistency of scientific evidence. Methods: This nested case-control study examined whether serum lycopene was associated with prostate cancer risk among participants in the Prostate Cancer Prevention Trial, a placebo-controlled trial of finasteride for prostate cancer prevention. Presence or absence of cancer was determined by prostate biopsy, recommended during the trial due to elevated prostate specific antigen (PSA) level or abnormal digital rectal examination (DRE) and offered to all men at the trial end. There were 1,683 cases (461 Gleason score ≥ 7, 125 Gleason score ≥ 8) and 1,751 controls. Results: There were no associations of lycopene with prostate cancer risk. The odds ratios for a linear increase in lycopene (per 10 mg/dL) were 0.99 (95% CI: 0.94-1.04), 1.01 (0.94-1.08), and 1.02 (0.90-1.15) for Gleason 2 to 6, 7 to 10, and 8 to 10, respectively. In the placebo arm, a 10 mg/dL increase in lycopene was associated with a 7% (95% CI: 14-0) reduced risk of cancer diagnosed following an elevated PSA or abnormal DRE, which are cancers that best match those detected in screened populations. However, a 10 mg/dL increase in lycopene was also associated with an 8% (95% CI: 1-16) increased risk of cancer diagnosed without a biopsy prompt, which are cancers generally not detected. These findings were similar for low- and high-grade cancer. Conclusion: This study does not support a role for lycopene in prostate cancer prevention. Impact: Scientists and the public should understand that early studies supporting an association of dietary lycopene with reduced prostate cancer risk have not been replicated in studies using serum biomarkers of lycopene intake. Recommendations of professional societies to the public should be modified to reflect the likelihood that increasing lycopene intake will not affect prostate cancer risk.

Original languageEnglish (US)
Pages (from-to)638-646
Number of pages9
JournalCancer Epidemiology Biomarkers and Prevention
Volume20
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Prostatic Neoplasms
Serum
Digital Rectal Examination
Neoplasms
Neoplasm Grading
Prostate-Specific Antigen
Placebos
lycopene
Finasteride
Biopsy
Case-Control Studies
Prostate
Biomarkers
Odds Ratio
Population

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Serum lycopene concentration and prostate cancer risk : Results from the prostate cancer prevention trial. / Kristal, Alan R.; Till, Cathee; Platz, Elizabeth A.; Song, Xiaoling; King, Irena B.; Neuhouser, Marian L.; Ambrosone, Christine B.; Thompson, Ian M.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 20, No. 4, 04.2011, p. 638-646.

Research output: Contribution to journalArticle

Kristal, AR, Till, C, Platz, EA, Song, X, King, IB, Neuhouser, ML, Ambrosone, CB & Thompson, IM 2011, 'Serum lycopene concentration and prostate cancer risk: Results from the prostate cancer prevention trial', Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 4, pp. 638-646. https://doi.org/10.1158/1055-9965.EPI-10-1221
Kristal, Alan R. ; Till, Cathee ; Platz, Elizabeth A. ; Song, Xiaoling ; King, Irena B. ; Neuhouser, Marian L. ; Ambrosone, Christine B. ; Thompson, Ian M. / Serum lycopene concentration and prostate cancer risk : Results from the prostate cancer prevention trial. In: Cancer Epidemiology Biomarkers and Prevention. 2011 ; Vol. 20, No. 4. pp. 638-646.
@article{c9ea195c1978424aaa2f6afbd6d75584,
title = "Serum lycopene concentration and prostate cancer risk: Results from the prostate cancer prevention trial",
abstract = "Background: Lycopene has been promoted for prostate cancer prevention, despite the inconsistency of scientific evidence. Methods: This nested case-control study examined whether serum lycopene was associated with prostate cancer risk among participants in the Prostate Cancer Prevention Trial, a placebo-controlled trial of finasteride for prostate cancer prevention. Presence or absence of cancer was determined by prostate biopsy, recommended during the trial due to elevated prostate specific antigen (PSA) level or abnormal digital rectal examination (DRE) and offered to all men at the trial end. There were 1,683 cases (461 Gleason score ≥ 7, 125 Gleason score ≥ 8) and 1,751 controls. Results: There were no associations of lycopene with prostate cancer risk. The odds ratios for a linear increase in lycopene (per 10 mg/dL) were 0.99 (95{\%} CI: 0.94-1.04), 1.01 (0.94-1.08), and 1.02 (0.90-1.15) for Gleason 2 to 6, 7 to 10, and 8 to 10, respectively. In the placebo arm, a 10 mg/dL increase in lycopene was associated with a 7{\%} (95{\%} CI: 14-0) reduced risk of cancer diagnosed following an elevated PSA or abnormal DRE, which are cancers that best match those detected in screened populations. However, a 10 mg/dL increase in lycopene was also associated with an 8{\%} (95{\%} CI: 1-16) increased risk of cancer diagnosed without a biopsy prompt, which are cancers generally not detected. These findings were similar for low- and high-grade cancer. Conclusion: This study does not support a role for lycopene in prostate cancer prevention. Impact: Scientists and the public should understand that early studies supporting an association of dietary lycopene with reduced prostate cancer risk have not been replicated in studies using serum biomarkers of lycopene intake. Recommendations of professional societies to the public should be modified to reflect the likelihood that increasing lycopene intake will not affect prostate cancer risk.",
author = "Kristal, {Alan R.} and Cathee Till and Platz, {Elizabeth A.} and Xiaoling Song and King, {Irena B.} and Neuhouser, {Marian L.} and Ambrosone, {Christine B.} and Thompson, {Ian M.}",
year = "2011",
month = "4",
doi = "10.1158/1055-9965.EPI-10-1221",
language = "English (US)",
volume = "20",
pages = "638--646",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Serum lycopene concentration and prostate cancer risk

T2 - Results from the prostate cancer prevention trial

AU - Kristal, Alan R.

AU - Till, Cathee

AU - Platz, Elizabeth A.

AU - Song, Xiaoling

AU - King, Irena B.

AU - Neuhouser, Marian L.

AU - Ambrosone, Christine B.

AU - Thompson, Ian M.

PY - 2011/4

Y1 - 2011/4

N2 - Background: Lycopene has been promoted for prostate cancer prevention, despite the inconsistency of scientific evidence. Methods: This nested case-control study examined whether serum lycopene was associated with prostate cancer risk among participants in the Prostate Cancer Prevention Trial, a placebo-controlled trial of finasteride for prostate cancer prevention. Presence or absence of cancer was determined by prostate biopsy, recommended during the trial due to elevated prostate specific antigen (PSA) level or abnormal digital rectal examination (DRE) and offered to all men at the trial end. There were 1,683 cases (461 Gleason score ≥ 7, 125 Gleason score ≥ 8) and 1,751 controls. Results: There were no associations of lycopene with prostate cancer risk. The odds ratios for a linear increase in lycopene (per 10 mg/dL) were 0.99 (95% CI: 0.94-1.04), 1.01 (0.94-1.08), and 1.02 (0.90-1.15) for Gleason 2 to 6, 7 to 10, and 8 to 10, respectively. In the placebo arm, a 10 mg/dL increase in lycopene was associated with a 7% (95% CI: 14-0) reduced risk of cancer diagnosed following an elevated PSA or abnormal DRE, which are cancers that best match those detected in screened populations. However, a 10 mg/dL increase in lycopene was also associated with an 8% (95% CI: 1-16) increased risk of cancer diagnosed without a biopsy prompt, which are cancers generally not detected. These findings were similar for low- and high-grade cancer. Conclusion: This study does not support a role for lycopene in prostate cancer prevention. Impact: Scientists and the public should understand that early studies supporting an association of dietary lycopene with reduced prostate cancer risk have not been replicated in studies using serum biomarkers of lycopene intake. Recommendations of professional societies to the public should be modified to reflect the likelihood that increasing lycopene intake will not affect prostate cancer risk.

AB - Background: Lycopene has been promoted for prostate cancer prevention, despite the inconsistency of scientific evidence. Methods: This nested case-control study examined whether serum lycopene was associated with prostate cancer risk among participants in the Prostate Cancer Prevention Trial, a placebo-controlled trial of finasteride for prostate cancer prevention. Presence or absence of cancer was determined by prostate biopsy, recommended during the trial due to elevated prostate specific antigen (PSA) level or abnormal digital rectal examination (DRE) and offered to all men at the trial end. There were 1,683 cases (461 Gleason score ≥ 7, 125 Gleason score ≥ 8) and 1,751 controls. Results: There were no associations of lycopene with prostate cancer risk. The odds ratios for a linear increase in lycopene (per 10 mg/dL) were 0.99 (95% CI: 0.94-1.04), 1.01 (0.94-1.08), and 1.02 (0.90-1.15) for Gleason 2 to 6, 7 to 10, and 8 to 10, respectively. In the placebo arm, a 10 mg/dL increase in lycopene was associated with a 7% (95% CI: 14-0) reduced risk of cancer diagnosed following an elevated PSA or abnormal DRE, which are cancers that best match those detected in screened populations. However, a 10 mg/dL increase in lycopene was also associated with an 8% (95% CI: 1-16) increased risk of cancer diagnosed without a biopsy prompt, which are cancers generally not detected. These findings were similar for low- and high-grade cancer. Conclusion: This study does not support a role for lycopene in prostate cancer prevention. Impact: Scientists and the public should understand that early studies supporting an association of dietary lycopene with reduced prostate cancer risk have not been replicated in studies using serum biomarkers of lycopene intake. Recommendations of professional societies to the public should be modified to reflect the likelihood that increasing lycopene intake will not affect prostate cancer risk.

UR - http://www.scopus.com/inward/record.url?scp=79955773122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955773122&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-10-1221

DO - 10.1158/1055-9965.EPI-10-1221

M3 - Article

C2 - 21335507

AN - SCOPUS:79955773122

VL - 20

SP - 638

EP - 646

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 4

ER -